Berlin

• A research study looking at how different doses of study medicine (Inno8) work in the body of people with haemophilia A Recruiting
  2025-520490-38-00 3 2025-10-13 Haemophilia A with or without inhibitors. Proposed indication under de
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting
  2024-516652-18-00 5 2025-10-10 Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
• A study to learn how the study drug bimekizumab works and how safe it is in treating moderate to severe hidradenitis suppurativa in children … Recruiting
  2023-505323-31-00 5 2025-10-09 Hidradenitis Suppurativa
• Study of zoldonrasib with or without daraxonrasib and other anticancer drugs in patients with RAS G12D-mutant non-small cell lung cancer (NS … Recruiting
  2025-521147-21-00 4 2025-10-08 Lung Cancer
• Efficacy and safety of remibrutinib after switching from ocrelizumab in participants living with relapsing multiple sclerosis, followed by o … Recruiting
  2023-509275-17-00 5 2025-10-06 Relapsing multiple sclerosis
• A clinical trial to evaluate efficacy and safety of Xeomin® injections for preventing chronic migraine Recruiting
  2024-515682-34-00 5 2025-10-06 Chronic migraine
• A clinical trial to evaluate efficacy and safety of Xeomin® injections for preventing episodic migraine Recruiting
  2024-515715-22-00 5 2025-10-06 Episodic migraine
• Study of Ruxolitinib Cream in Participants with Hidradenitis Suppurativa (TRuE-HS1) Recruiting
  2024-517632-22-00 5 2025-10-06 Hidradenitis Suppurativa
• A study to test a new immunotherapy, ABX-001, alone and in combination with the marketed drug, pembrolizumab, for the treatment of tumors pr … Recruiting
  2024-512403-39-01 1 2025-10-03 Advanced Solid Tumors Who Are Beyond Standard of Care
• Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Platinum Resistant Ovarian Cancer Recruiting
  2024-514822-21-00 5 2025-10-02 Platinum-resistant Ovarian Cancer
• Efficacy and safety of trifluridin/tipiracil in combination with nanoliposomal irinotecan as a second line therapy in patients with cholangi … Recruiting
  2024-517330-18-00 4 2025-10-02 advanced, non resectable or metastatic cholangio- or gallbladder carci
• Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Recruiting
  2023-509861-19-01 4 2025-09-30 High-grade B-cell lymphoma (HGBL)
• Using lab-grown mini-tumors from pancreatic cancer tissue to predict and improve post-surgery treatment for pancreatic cancer Recruiting
  2023-510490-34-00 4 2025-09-29 Patients with functionally resectable pancreatic ductal adenocarcinoma
• A study to investigate the effect of AZD6793 in participants with moderate to very severe chronic obstructive pulmonary disease Recruiting
  2025-520473-40-00 4 2025-09-29 Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
• A clinical study of MK-1084 with targeted therapy and chemotherapy in people with colorectal cancer (MK-1084-012). Recruiting
  2024-517232-22-00 5 2025-09-26 KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorect
• Long Term Study of Livmarli Recruiting
  2024-516804-40-00 6 2025-09-25 Progressive Familial Intrahepatic Cholestasis
• A trial to learn how safe baxdrostat is and how well it works in adults with primary aldosteronism Recruiting
  2025-520740-16-00 5 2025-09-19 Primary Aldosteronism defined by excess aldosterone secretion
• A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B) Recruiting
  2024-513613-12-00 9 2025-09-18 Part A: Healthy volunteers (Part A is not applicable to the EU; for in
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-line Treatment of PD-L1-high Metastatic Non-small Cell Lung … Recruiting
  2024-517780-24-00 5 2025-09-18 Lung Cancer
• CATALINA-2: A Phase 2 Study of TORL-1-23 in Advanced Ovarian Cancer Recruiting
  2024-517190-24-00 4 2025-09-16 Peritoneal Cancer
• Evaluation of efficacy and safety of GSK5764227 (alone and in combination) in participants with previously treated advanced unresectable or … Recruiting
  2025-520672-26-00 9 2025-09-16 Gastrointestinal Neoplasms
• An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients with Myotonic Dystrophy … Recruiting
  2024-511178-66-00 5 2025-09-12 Myotonic Dystrophy type 1 and type 2 (DM1/DM2)
• A study to evaluate the efficacy and safety of ruxolitinib cream in children (6 to <12 years old) with non-segmental vitiligo Recruiting
  2024-513171-41-00 5 2025-09-11 Vitiligo
• Study of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer … Recruiting
  2024-516982-35-00 5 2025-09-11 Ovarian Cancer

Showing 457–480 of 1,776 trials